Categories: News

Remi Tech Ushers in a New Era of Compliant Stablecoin Settlement — Empowering Traditional Finance and Compliant Web3 with Next-Gen Infrastructure

SINGAPORE, Sept. 10, 2025 /PRNewswire/ — Remi Technology, a pioneer in compliant digital finance solutions, today launched the Remi Global Stablecoin Clearing System—a first-of-its-kind infrastructure integrating banking-grade settlement with built-in AML/CFT and RegTech capabilities. This breakthrough redefines cross-border finance by merging stablecoin efficiency with regulatory certainty for banks, financial institutions, and Web3 enterprises.

- Advertisement -

A New Standard for Compliant Digital Finance

- Advertisement -

The Remi System delivers a regulation-ready framework for stablecoin issuance, trading, and settlement, addressing critical pain points in global payments:

- Advertisement -
  • Instant, low-cost interbank transactions with embedded compliance
  • Real-time liquidity via full integration with traditional banking systems
  • Live regulatory oversight for transparent, auditable workflows
  • Robust AML/CFT controls to protect institutions and users from illicit funds

Remi Tech’s RegTech innovation delivers a unified on-chain/off-chain KYC infrastructure, complemented by three dedicated regulatory dashboards: Real-Time Screening, AML, and Operational Monitoring. These provide regulators with real-time data access and advanced monitoring capabilities.

- Advertisement -

By combining FinTech with RegTech in one KYC framework, Remi eliminates the speed-compliance trade-off, enabling secure and efficient inter-institutional transactions. It also delivers real-time insights to monetary policymakers via regulatory dashboards.

- Advertisement -

The system includes a dedicated module to help central banks monitor key stablecoin metrics—such as interest rates, M0, M2, and exchange rates—across onshore and offshore markets. It allows authorities to assess impacts on monetary policy transmission and prevent sharp rate fluctuations in interest and exchange rates.

- Advertisement -

Remi’s solution also features:

- Advertisement -
  • Automated regulatory reporting
  • AI-driven transaction monitoring
  • Jurisdictional compliance tracking

“Traditional finance prioritizes security and compliance, while Web3 emphasizes efficiency. Remi uniquely resolves this trilemma with a seamless, unified solution,” stated YongCheng Zhang, CTO of Remi Tech, “Our platform enables banks and digital asset issuers to harness stablecoins’ potential—without regulatory compromise. It builds the foundation for a new era of global financial connectivity.”

- Advertisement -

Industry Firsts: Why Remi Stands Apart

- Advertisement -
  1. First instant stablecoin-powered interbank settlement network with low costs
  2. First stablecoin platform fully integrated with banking systems
  3. First stablecoin platform with embedded AML/CFT capabilities
  4. First stablecoin platform enabling real-time regulatory oversight
  5. First stablecoin platform enabling FX trading
  6. First end-to-end solutions empowering stablecoin ecosystem

About Remi Technology

- Advertisement -

Remi Technology is a Singapore-based fintech company that delivers stablecoin clearing and settlement infrastructures for banks and financial institutions worldwide. Find us at www.remitech.ai or www.linkedin.com/company/remi-tech.

- Advertisement -

Contact:
Remi Business Development Team: 
bd@remitech.ai 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/remi-tech-ushers-in-a-new-era-of-compliant-stablecoin-settlement–empowering-traditional-finance-and-compliant-web3-with-next-gen-infrastructure-302550135.html

- Advertisement -

Recent Posts

Deepak Group Goes Beyond Green with hands-On Mangrove Restoration

Deepak Group undertakes mangrove plantation drive on World Environment DaySustainable restoration along the Paniyadra coast,…

12 hours ago

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction,…

16 hours ago

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as…

16 hours ago

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)…

16 hours ago

Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

June 05, 2026 20:13 ET  | Source: Bluejay Diagnostics, Inc. $8.5 million upfront with up…

16 hours ago